aTyr Pharma (LIFE)
(Delayed Data from NSDQ)
$NA USD
0 (0.00%)
Updated Dec 31, 1969 06:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
aTyr Pharma, Inc. [LIFE]
Reports for Purchase
Showing records 41 - 60 ( 174 total )
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Efzofitimod On Track; Updated Phase 1b/2a Data Presentation at ATS
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
AACR Preclinical Data Further Demonstrate Potential For ATYR2810 in Aggressive Solid Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 - Key Study Initiations in Sarcoidosis & Solid Tumors During 2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; Efzofitimod Getting Ready to Go Pivotal; ATYR2810 to Begin Phase 1
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; ATYR1923 Awaits Guidance; ATYR2810 Advances to the Clinic; Target Adjusted to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Update - Two Key Catalysts Should Be on Your Radar For 2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Worth the Wait; Strong Sarcoidosis Signals Especially on Steroid Tapering; Target Upped to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Pulmonary Sarcoidosis Data Exceeds Expectations - Increasing PT to $21
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
KOL Helps Set Expectations For Upcoming Sarcoidosis Data in Mid-Sept.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Update; Pulmonary Sarcoidosis Data Reaffirmed Mid-September - $20 PT
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; ATYR1923 Read-Out in Sarcoidosis Expected Mid-September
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z